Micofenolato Mofetile Sandoz

Mycophenolate Mofetil, the active ingredient in Micofenolato Mofetile Sandoz, is an immunosuppressant presented as an oral formulation for oral use. It is used to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients, including kidney, heart and liver transplant recipients. GNH USA supplies Micofenolato Mofetile Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is an antimetabolite immunosuppressant used in conditions where inhibition of lymphocyte proliferation is required. - Kidney transplant: helps prevent acute and chronic graft rejection. - Heart transplant: reduces the risk of graft rejection. - Liver transplant: supports graft survival by suppressing immune response. - Lupus nephritis: improves renal outcomes by decreasing immune‑mediated inflammation.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: frequent loose stools. - Vomiting: occasional episodes. - Headache: transient mild headache.

Serious or Rare Side Effects: - Infections: heightened risk of bacterial, viral, and fungal infections. - Leukopenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Pregnancy complications: potential fetal harm (Category D).

When prescribing Mycophenolate Mofetile Sandoz, clinicians should observe several safety measures. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate renal function: adjust use in impaired kidneys. - Avoid live vaccines: increased infection risk. - Pregnancy risk: contraindicated in pregnancy (Category D); use effective contraception. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Mycophenolate Mofetile Sandoz can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: may reduce absorption. - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increased mycophenolate exposure, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Rifampin: may decrease mycophenolate plasma levels. - Valganciclovir: potential additive hematologic effects. - Live vaccines: increased infection risk, requiring caution.